

Panniculitis in association with target therapy in melanoma patient, what the dermatologist should know: A case report

Por: [Manubens-Vargas, V](#) (Manubens-Vargas, Victor)¹; [Rodriguez-Ortubia, M](#) (Rodriguez-Ortubia, Manuel)¹; [Salas-Gianini, A](#) (Salas-Gianini, Alejandra)¹; [Valenzuela, F](#) (Valenzuela, Fernando)¹; [Carreno-Toro, L](#) (Carreno-Toro, Laura)²

[Ver número de ResearchID y ORCID de Web of Science](#)

MEDWAVE

Volumen: 20

Número: 7

Número de artículo: e8010

DOI: 10.5867/medwave.2020.07.8010

Fecha de publicación: AUG 2020

Tipo de documento: Article

Abstract

Target therapies are currently a therapeutic option increasingly used for the management of patients with metastatic melanoma. However, there are multiple adverse pharmacological effects associated with their use that have been described. Cutaneous adverse reactions are the most frequent. We report the case of a 55-year-old man with a diagnosis of stage IV BRAFV600E-mutated metastatic cutaneous melanoma undergoing treatment with dabrafenib/trametinib, who consulted due to the development of erythematous nodular lesions in the upper and lower limbs associated with febrile sensation during the course of treatment. Infection was ruled out and a biopsy of the skin lesions was done, which provided the histopathological confirmation of a predominantly septal, granulomatous with leukocytoclastic vasculitis, mixed panniculitis. Panniculitis associated with this therapy has been described in the literature and has been considered an immune-mediated pharmacological adverse effect. It is considered to be related to a better prognosis in the treatment of metastatic melanoma. Consequently, as shown in this case report, target therapy should not be discontinued and symptomatic medication should be given to alleviate patient discomfort. The dermatologist should know and properly interpret this adverse effect and prescribe the most appropriate management for the patient.

Palabras clave

Palabras clave de autor: [melanoma](#); [panniculitis](#); [BRAF kinases](#); [adverse drug reaction](#)

KeyWords Plus: [BRAF INHIBITORS](#)

Información del autor

Dirección para petición de copias:

Universidad de Chile Univ Chile, Fac Med, Dept Dermatol, Santiago, Chile.

Dirección correspondiente: Manubens-Vargas, V (autor correspondiente)

+ Univ Chile, Fac Med, Dept Dermatol, Santiago, Chile.

Direcciones:

+ [1] Univ Chile, Fac Med, Dept Dermatol, Santiago, Chile

+ [2] Hosp Clin Univ Chile, Serv Anat Patol, Santiago, Chile

Direcciones de correo electrónico:victor.manubens.v@gmail.com

Editorial

MEDWAVE ESTUDIOS LTD, VILLASECA 21 OFIC 702, SANTIAGO DE CHILE, 00000, CHILE

Categorías / Clasificación

Áreas de investigación:General & Internal Medicine

Categorías de Web of Science:Medicine, General & Internal

Información del documento

Idioma:Spanish

Número de acceso: WOS:000603367000012

ID de PubMed: 32877390

ISSN: 0717-6384